Citi raised the firm’s price target on Danaher to $280 from $255 and keeps a Buy rating on the shares. While the initial bioprocessing guidance came in below expectations, investor focus has shifted to the fiscal 2024 exit rate and recovery story, the analyst tells investors in a research note. The firm sees more visibility into Danaher’s recovery post the Q4 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DHR:
- Danaher Corporation Reports Earnings: Did it Beat Estimate Forecasts?
- Danaher (NYSE:DHR) Drops on Dismal Q4 Numbers
- Danaher sees FY24 revenue down low-single digits, consensus $24.05B
- Danaher sees Q1 revenue down high-single digits, consensus $5.73B
- Danaher Reports Fourth Quarter and Full Year 2023 Results
